Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
537
Recruiting Now
537
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT06951503 Phase 3
Recruiting
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Condition
Colorectal Adenocarcinoma
Enrollment
560 pts
Location
China
Sponsor
Akeso
NCT06998524 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Typ...
Condition
Von Willebrand Disease, Type 3
Enrollment
75 pts
Location
United States, Belgium, Canada
Sponsor
Hoffmann-La Roche
NCT07759154 Phase 3
Recruiting
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hy...
Condition
Attention-deficit/Hyperactivity Disorder
Enrollment
80 pts
Location
United States
Sponsor
Otsuka Pharmaceutical Developm
NCT07817251 Phase 3
Recruiting
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semagl...
Condition
Diabetes Mellitus, Type 2
Enrollment
210 pts
Location
United States
Sponsor
Novo Nordisk A/S
NCT07842172 Phase 3
Recruiting
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Thera...
Condition
Neuroendocrine Neoplasm
Enrollment
240 pts
Location
United States
Sponsor
Washington University School o
NCT07721961 Phase 3
Recruiting
A Study of MI078 for Postpartum Depression
Condition
Postpartum Depression (PPD)
Enrollment
200 pts
Location
China
Sponsor
Nanjing Minova Pharmaceutical
NCT07369154 Phase 3
Recruiting
52-week Open Label Safety-Tolerability Study
Condition
Schizophrenia
Enrollment
900 pts
Location
United States
Sponsor
LB Pharmaceuticals Inc.
NCT07649122 Phase 3
Recruiting
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT...
Condition
Prostate Cancer
Enrollment
232 pts
Location
China
Sponsor
Norroy Bioscience Co., LTD
NCT06650579 Phase 3
Recruiting
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Tr...
Condition
Recurrent Prostate Carcinoma
Enrollment
72 pts
Location
United States
Sponsor
Emory University
NCT04853342 Phase 3
Recruiting
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients W...
Condition
Non-small Cell Lung Carcinoma
Enrollment
318 pts
Location
China
Sponsor
Allist Pharmaceuticals, Inc.
NCT07541079 Phase 3
Recruiting
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Gir...
Condition
Early Breast Cancer
Enrollment
300 pts
Location
United States
Sponsor
Genentech, Inc.
NCT07174427 Phase 3
Recruiting
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patien...
Condition
Synovial Sarcomas
Enrollment
5 pts
Location
Japan
Sponsor
Takara Bio Inc.
NCT06095583 Phase 3
Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consol...
Condition
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Enrollment
756 pts
Location
China, Georgia, Netherlands
Sponsor
Shanghai Junshi Bioscience Co.
NCT07265674 Phase 3
Recruiting
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (P...
Condition
Advanced Biliary Tract Cancer
Enrollment
480 pts
Location
United States
Sponsor
J-Pharma Co., Ltd.
NCT06767514 Phase 3
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patie...
Condition
Non-Small Cell Lung Cancer
Enrollment
780 pts
Location
United States, Belgium, Canada
Sponsor
Summit Therapeutics
NCT07116967 Phase 3
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants Wit...
Condition
Plaque Psoriasis
Enrollment
3,040 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT06134492 Phase 3
Recruiting
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
Condition
Pneumonia, Viral
Enrollment
616 pts
Location
Germany
Sponsor
Jena University Hospital
NCT05314998 Phase 3
Recruiting
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxalip...
Condition
Pancreatic Ductal Adenocarcinoma
Enrollment
394 pts
Location
Germany, Sweden
Sponsor
John Neoptolemos
NCT05407987 Phase 3
Recruiting
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS ...
Condition
Gynecologic Cancer
Enrollment
82 pts
Location
Canada
Sponsor
AHS Cancer Control Alberta
NCT06740630 Phase 3
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vacci...
Condition
Chickenpox
Enrollment
1,840 pts
Location
United States, Belgium, Colombia
Sponsor
GlaxoSmithKline
NCT03823534 Phase 3
Recruiting
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Condition
Bone Metastases
Enrollment
60 pts
Location
United States
Sponsor
St. Louis University
NCT07168434 Phase 3
Recruiting
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
Condition
IBS (Irritable Bowel Syndrome)
Enrollment
406 pts
Location
Portugal, Spain
Sponsor
Biocodex
NCT06619301 Phase 3
Recruiting
RCT Glargine vs NPH for Treatment of DM in Pregnancy
Condition
Diabetes Mellitus in Pregnancy
Enrollment
160 pts
Location
United States
Sponsor
Loyola University
NCT07770828 Phase 3
Recruiting
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic...
Condition
Dry Age-related Macular Degeneration
Enrollment
237 pts
Location
United States
Sponsor
Ocugen
NCT07551492 Phase 3
Recruiting
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants...
Condition
Atherosclerotic Cardiovascular Disease
Enrollment
9,262 pts
Location
China
Sponsor
Fujian Shengdi Pharmaceutical
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology